Log in

Relevant bibliographies by topics / Anticancer drugs / Journal articles

To see the other types of publications on this topic, follow the link: Anticancer drugs.

Journal articles on the topic 'Anticancer drugs'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Anticancer drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

D, Subba Reddy, Prasanthi G, Amruth Raj S, Hari Krishna T, Sowjanya K, and Shantha Kumari K. "EVALUATION OF ANTICANCER GENERIC DRUGS AND BRANDED DRUGS." Indian Research Journal of Pharmacy and Science 5, no. 1 (2018): 1378–91. http://dx.doi.org/10.21276/irjps.2018.5.1.16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Reese, David M. "Anticancer drugs." Nature 378, no. 6557 (1995): 532. http://dx.doi.org/10.1038/378532c0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Jorayev, Muhammadyusuf Abdurakhim ugli Juraev Mukhammadyusuf. "ANTICANCER DRUGS." INTERNATIONAL BULLETIN OF MEDICAL SCIENCES AND CLINICAL RESEARCH 3, no. 4 (2023): 114–17. https://doi.org/10.5281/zenodo.7854262.

Full text

Abstract:

The article presents an overview of anticancer drugs for medical use currently registered in Uzbekistan and at the final stage of their development - clinical trials in accredited testing centers for subsequent registration. The generalized information was obtained from official sources - the State Register of Medicines of the Ministry of Health of Uzbekistan, the Electronic Rubricator of Clinical Recommendations and Clinical Guidelines and orders on the Standards of Medical Care prepared on their basis. The place and role of chemotherapeutic agents in the treatment of oncological patients and

APA, Harvard, Vancouver, ISO, and other styles

4

Kutty, Dr A. V. M. "Usefulness of Phytochemicals as Anticancer Drugs." JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 16, no. 1 (2019): 1–2. http://dx.doi.org/10.58739/jcbs/v09i1.7.

Full text

Abstract:

Cancer is a state of uncontrolled proliferation and dedifferentiation of cells in any tissues or organs of the body. The incidence of cancer is rising alarmingly and is one of the leading causes of morbidity and mortality globally. Normal cell division is precisely a planned biological process controlled by regulatory genes and specific metabolic pathways. Exposure of normally functioning cells to carcinogens leads to mutations in the genes causing loss of control of cell division and transform into cancerous. Over a period of time, these cancer cells acquire more mutations; invade to adjoinin

APA, Harvard, Vancouver, ISO, and other styles

5

Atkins, Joshua H., and Leland J. Gershell. "Selective anticancer drugs." Nature Reviews Drug Discovery 1, no. 7 (2002): 491–92. http://dx.doi.org/10.1038/nrd842.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Atkins, Joshua H., and Leland J. Gershell. "Selective anticancer drugs." Nature Reviews Cancer 2, no. 9 (2002): 645–46. http://dx.doi.org/10.1038/nrc900.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bibby, M. C. "Combretastatin anticancer drugs." Drugs of the Future 27, no. 5 (2002): 475. http://dx.doi.org/10.1358/dof.2002.027.05.668645.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Meegan, Mary J., and Niamh M. O’Boyle. "Special Issue “Anticancer Drugs”." Pharmaceuticals 12, no. 3 (2019): 134. http://dx.doi.org/10.3390/ph12030134.

Full text

Abstract:

The focus of this Special Issue of Pharmaceuticals is on the design, synthesis, and molecular mechanism of action of novel antitumor, drugs with a special emphasis on the relationship between the chemical structure and the biological activity of the molecules. This Special Issue also provides an understanding of the biologic and genotypic context in which targets are selected for oncology drug discovery, thus providing a rationalization for the biological activity of these drugs and guiding the design of more effective agents. In this Special Issue of Pharmaceuticals dedicated to anticancer dr

APA, Harvard, Vancouver, ISO, and other styles

9

Ciarimboli, Giuliano. "Anticancer Platinum Drugs Update." Biomolecules 11, no. 11 (2021): 1637. http://dx.doi.org/10.3390/biom11111637.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Zhang, Jason Y. "Apoptosis-based anticancer drugs." Nature Reviews Drug Discovery 1, no. 2 (2002): 101–2. http://dx.doi.org/10.1038/nrd742.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Blagosklonny, Mikhail V. "Teratogens as Anticancer Drugs." Cell Cycle 4, no. 11 (2005): 1518–21. http://dx.doi.org/10.4161/cc.4.11.2208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

KOPEČEK, JINDŘICH. "Targetable Polymeric Anticancer Drugs." Annals of the New York Academy of Sciences 618, no. 1 Temporal Cont (1991): 335–44. http://dx.doi.org/10.1111/j.1749-6632.1991.tb27253.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Mundy, Gregory R., and Toshiyuki Yoneda. "Bisphosphonates as Anticancer Drugs." New England Journal of Medicine 339, no. 6 (1998): 398–400. http://dx.doi.org/10.1056/nejm199808063390609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Miyamoto, Shingo, Manabu Yamada, Yasuyo Kasai, Akito Miyauchi, and Kazumichi Andoh. "Anticancer drugs during pregnancy." Japanese Journal of Clinical Oncology 46, no. 9 (2016): 795–804. http://dx.doi.org/10.1093/jjco/hyw073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Xing, Z., D. Li, L. Yang, Y. Xi, and X. Su. "MicroRNAs and anticancer drugs." Acta Biochimica et Biophysica Sinica 46, no. 3 (2014): 233–39. http://dx.doi.org/10.1093/abbs/gmu003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Wallis, Denise, James Claffey, Brendan Gleeson, Megan Hogan, Helge Müller-Bunz, and Matthias Tacke. "Novel zirconocene anticancer drugs?" Journal of Organometallic Chemistry 694, no. 6 (2009): 828–33. http://dx.doi.org/10.1016/j.jorganchem.2008.08.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Bradley, David. "Self-assembling anticancer drugs." Materials Today 41 (December 2020): 3. http://dx.doi.org/10.1016/j.mattod.2020.10.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Russell, Stephen J., and Kah-Whye Peng. "Viruses as anticancer drugs." Trends in Pharmacological Sciences 28, no. 7 (2007): 326–33. http://dx.doi.org/10.1016/j.tips.2007.05.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Kerwin, Sean. "Toward Bioengineering Anticancer Drugs." Chemistry & Biology 9, no. 9 (2002): 956–58. http://dx.doi.org/10.1016/s1074-5521(02)00222-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Rohr, Jürgen. "Cryptophycin Anticancer Drugs Revisited." ACS Chemical Biology 1, no. 12 (2006): 747–50. http://dx.doi.org/10.1021/cb6004678.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Denny, William A. "Hypoxia-activated anticancer drugs." Expert Opinion on Therapeutic Patents 15, no. 6 (2005): 635–46. http://dx.doi.org/10.1517/13543776.15.6.635.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Bordon, Yvonne. "Anticancer drugs copy bugs." Nature Reviews Cancer 14, no. 12 (2014): 767. http://dx.doi.org/10.1038/nrc3866.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Van der Veldt, Astrid A. M., Adriaan A. Lammertsma, and Egbert F. Smit. "Scheduling of anticancer drugs." Cell Cycle 11, no. 23 (2012): 4339–43. http://dx.doi.org/10.4161/cc.22187.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Mundy, Gregory R. "Bisphosphonates as anticancer drugs." Expert Opinion on Investigational Drugs 8, no. 12 (1999): 2009–15. http://dx.doi.org/10.1517/13543784.8.12.2009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Bordon, Yvonne. "Anticancer drugs need bugs." Nature Reviews Immunology 14, no. 1 (2013): 1. http://dx.doi.org/10.1038/nri3591.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Bordon, Yvonne. "Anticancer drugs copy bugs." Nature Reviews Immunology 14, no. 12 (2014): 776–77. http://dx.doi.org/10.1038/nri3775.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Jefford, Michael, Linda Mileshkin, Penelope Schofield, Emilia Agalianos, Jacqui Thomson, and John Zalcberg. "Discussing Expensive Anticancer Drugs." Journal of Clinical Oncology 27, no. 3 (2009): 476–77. http://dx.doi.org/10.1200/jco.2008.20.1780.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Schwartsmann, G. "Anticancer drugs from nature." Medical and Pediatric Oncology 37, no. 1 (2001): 79–80. http://dx.doi.org/10.1002/mpo.1173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Maiborodin, I., A. O. Shumeikina, V. I. Maiborodina, and S. E. Krasilnikov. "Cardiotoxicity of Anticancer Drugs." Antibiot Khimioter = Antibiotics and Chemotherapy 69, no. 9-10 (2025): 91–107. https://doi.org/10.37489/0235-2990-2024-69-9-10-91-107.

Full text

Abstract:

An analysis of the literature for 2022 was carried out in order to study the latest data on the cardiotoxicity of antitumor drugs. The abundance of data on the pathogenesis of cardiotoxicity of even a single chemotherapeutic agent indicates the multifactorial effect and the characteristics of the individual sensitivity of each patient to a particular drug. Due to the multifactorial nature of the pathogenesis of cardiotoxicity, the clinical manifestations of this complication are also numerous. It should be taken into account that oncological patients could have suffered from various cardiovasc

APA, Harvard, Vancouver, ISO, and other styles

30

Janus, Nicolas. "Gastrointestinal Disorders and Toxicities Induced By Anticancer Drugs. Another Risk Factor of Bleeding in Cancer-Associated Thrombosis." Blood 136, Supplement 1 (2020): 36. http://dx.doi.org/10.1182/blood-2020-141814.

Full text

Abstract:

Introduction Anticancer treatments has been changing since decades, evolving from chemotherapy (platinum salts) to recent check-point inhibitors. Nausea, vomiting and diarrhoea are common adverse events of anticancer drugs, despites the fact that some supportive care drugs can manage these adverse events. Gastro-intestinal (GI) disorders/toxicities are also important. Such as gastric/duodenal ulcer, gastritis, stomatitis, colitis, esophagitis... Cancer-associated-thrombosis (CAT) patients were also reported to be exposed to such GI disorders/toxicities and several publications recommended to c

APA, Harvard, Vancouver, ISO, and other styles

31

Pavan, Sable* Mangesh Randive Amol Shirode. "Medicinal Chemistry of Anticancer Drugs." International Journal of Pharmaceutical Sciences 3, no. 4 (2025): 171–1720. https://doi.org/10.5281/zenodo.15209176.

Full text

Abstract:

In recent decades, combating cancer and preventing its onset have become major priorities for healthcare systems worldwide. Significant progress has been made in both treating various types of cancer and improving survival rates, thanks to advancements in therapeutic methods and the development of effective antitumor drugs. Today, the discovery and creation of anticancer medications are key areas of focus for pharmaceutical companies, research institutions, and both government and non-government organizations globally. Remarkable strides have been made in identifying and developing drugs that

APA, Harvard, Vancouver, ISO, and other styles

32

Jia, Shuailong, Runjing Wang, Kui Wu, Hongliang Jiang, and Zhifeng Du. "Elucidation of the Mechanism of Action for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics." Molecules 24, no. 3 (2019): 581. http://dx.doi.org/10.3390/molecules24030581.

Full text

Abstract:

The discovery of the anticancer activity of cisplatin and its clinical application has opened a new field for studying metal-coordinated anticancer drugs. Metal-based anticancer drugs, such as cisplatin, can be transported to cells after entering into the human body and form metal–DNA or metal–protein adducts. Then, responding proteins will recognize adducts and form stable complexes. The proteins that were binding with metal-based anticancer drugs were relevant to their mechanism of action. Herein, investigation of the recognition between metal-based anticancer drugs and its binding partners

APA, Harvard, Vancouver, ISO, and other styles

33

Jiso, Apisada, Phisit Khemawoot, Pinnakarn Techapichetvanich, et al. "Drug-Herb Interactions among Thai Herbs and Anticancer Drugs: A Scoping Review." Pharmaceuticals 15, no. 2 (2022): 146. http://dx.doi.org/10.3390/ph15020146.

Full text

Abstract:

More than half of Thai patients with cancer take herbal preparations while receiving anticancer therapy. There is no systematic or scoping review on interactions between anticancer drugs and Thai herbs, although several research articles have that Thai herbs inhibit cytochrome P450 (CYP) or efflux transporter. Therefore, we gathered and integrated information related to the interactions between anticancer drugs and Thai herbs. Fifty-two anticancer drugs from the 2020 Thailand National List of Essential Medicines and 75 herbs from the 2020 Thai Herbal Pharmacopoeia were selected to determine po

APA, Harvard, Vancouver, ISO, and other styles

34

Li, Dong Hong, Jun Lin Diao, Ke Gui Yu, and Cheng He Zhou. "Synthesis and anticancer activities of porphyrin induced anticancer drugs." Chinese Chemical Letters 18, no. 11 (2007): 1331–34. http://dx.doi.org/10.1016/j.cclet.2007.09.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Anticancer drugs from the sea." Inpharma Weekly &NA;, no. 1417 (2003): 4. http://dx.doi.org/10.2165/00128413-200314170-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Evans, William E., and Mary V. Relling. "Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer Drugs." Clinical Pharmacokinetics 16, no. 6 (1989): 327–36. http://dx.doi.org/10.2165/00003088-198916060-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Carcone, Bernard, and Dionyssis Pongas. "Cardiovascular toxicity of anticancer drugs." Sang thrombose vaisseaux 26, no. 4 (2014): 188–96. http://dx.doi.org/10.1684/stv.2014.0849.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Amelio, Ivano, Andrey Lisitsa, Richard Knight, Gerry Melino, and Alexey Antonov. "Polypharmacology of Approved Anticancer Drugs." Current Drug Targets 18, no. 5 (2017): 534–43. http://dx.doi.org/10.2174/1389450117666160301095233.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Jeanny B. Aragon-Ching, Haiqing Li, Erin R. Gardner, and William D. Figg. "Thalidomide Analogues as Anticancer Drugs." Recent Patents on Anti-Cancer Drug Discovery 2, no. 2 (2007): 167–74. http://dx.doi.org/10.2174/157489207780832478.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Meegan, Mary J., and Niamh M. O’Boyle. "Special Issue “Anticancer Drugs 2021”." Pharmaceuticals 15, no. 4 (2022): 479. http://dx.doi.org/10.3390/ph15040479.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Benjamin Garbutcheon-Singh, K., Maxine P. Grant, Benjamin W. Harper, et al. "Transition Metal Based Anticancer Drugs." Current Topics in Medicinal Chemistry 11, no. 5 (2011): 521–42. http://dx.doi.org/10.2174/156802611794785226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Fujita, Ken-ichi. "Cytochrome P450 and Anticancer Drugs." Current Drug Metabolism 7, no. 1 (2006): 23–37. http://dx.doi.org/10.2174/138920006774832587.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Wallace, H. M., and A. V. Fraser. "Polyamine analogues as anticancer drugs." Biochemical Society Transactions 31, no. 2 (2003): 393–96. http://dx.doi.org/10.1042/bst0310393.

Full text

Abstract:

Just over 30 years ago, the late Diane Russell published the first in a series of papers linking polyamines and cancer. These early studies led to a flurry of research activity in the polyamine field that continues to this day attempting to identify a role for the polyamines in cancer development, treatment and/or prevention. The recognition that polyamines are critical for the growth of cancer cells, and consequently the identification of their metabolic pathways as a target for therapeutic intervention, led to the development of a number of useful inhibitors of polyamine biosynthesis. Arguab

APA, Harvard, Vancouver, ISO, and other styles

44

Hyodo, Kenji, Eiichi Yamamoto, Takuya Suzuki, Hiroshi Kikuchi, Makoto Asano, and Hiroshi Ishihara. "Development of Liposomal Anticancer Drugs." Biological and Pharmaceutical Bulletin 36, no. 5 (2013): 703–7. http://dx.doi.org/10.1248/bpb.b12-01106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Powis, Garth, Miles P. Hacker, and Graziano C. Carlon. "The Toxicity of Anticancer Drugs." Critical Care Medicine 21, no. 7 (1993): 1101. http://dx.doi.org/10.1097/00003246-199307000-00034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Chaudhary, Arpna, and G. Kaur. "Sustainability in anticancer drugs development." E3S Web of Conferences 552 (2024): 01069. http://dx.doi.org/10.1051/e3sconf/202455201069.

Full text

Abstract:

Cancer remains one of the most fatal disease threats to mankind. As the development of healthcare and medical science it is important to come up with a sustainable solution to deal with cancer treatment. Despite the fact that many of the approved drugs still exhibit high systemic toxicity, primarily as a result of their lack of tumor selectivity and current pharmacokinetic drawbacks (such as low water solubility), which adversely affect drug circulation time and bioavailability, anticancer research has produced impressive results in recent decades. The sensitivity of anticancer medications to

APA, Harvard, Vancouver, ISO, and other styles

47

Baumann, F., and R. Preiss. "Cyclophosphamide and related anticancer drugs." Journal of Chromatography B: Biomedical Sciences and Applications 764, no. 1-2 (2001): 173–92. http://dx.doi.org/10.1016/s0378-4347(01)00279-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Tjaden, U. R., and E. A. De Bruijn. "Chromatographic analysis of anticancer drugs." Journal of Chromatography B: Biomedical Sciences and Applications 531 (October 1990): 235–94. http://dx.doi.org/10.1016/s0378-4347(00)82286-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Sapra, P., and T. M. Allen. "Ligand-targeted liposomal anticancer drugs." Progress in Lipid Research 42, no. 5 (2003): 439–62. http://dx.doi.org/10.1016/s0163-7827(03)00032-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Tanigawara, Y. "Pharmaco-Metabolomics for Anticancer Drugs." Annals of Oncology 23 (October 2012): xi55. http://dx.doi.org/10.1016/s0923-7534(20)32076-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!